Amicus Therapeutics Current Ratio 2007-2021 | FOLD
For a detailed definition, formula and example for Current Ratio, check out our new background page here.
Amicus Therapeutics current ratio from 2007 to 2021. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations.
| Amicus Therapeutics Current Ratio Historical Data |
| Date |
Current Assets |
Current Liabilities |
Current Ratio |
| 2021-06-30 |
$0.48B |
$0.11B |
4.29 |
| 2021-03-31 |
$0.50B |
$0.10B |
5.05 |
| 2020-12-31 |
$0.58B |
$0.13B |
4.47 |
| 2020-09-30 |
$0.59B |
$0.11B |
5.24 |
| 2020-06-30 |
$0.38B |
$0.11B |
3.55 |
| 2020-03-31 |
$0.41B |
$0.09B |
4.45 |
| 2019-12-31 |
$0.52B |
$0.13B |
4.04 |
| 2019-09-30 |
$0.58B |
$0.09B |
6.20 |
| 2019-06-30 |
$0.64B |
$0.09B |
7.09 |
| 2019-03-31 |
$0.48B |
$0.07B |
7.33 |
| 2018-12-31 |
$0.55B |
$0.09B |
6.40 |
| 2018-09-30 |
$0.60B |
$0.07B |
9.12 |
| 2018-06-30 |
$0.58B |
$0.05B |
10.88 |
| 2018-03-31 |
$0.59B |
$0.14B |
4.21 |
| 2017-12-31 |
$0.39B |
$0.07B |
5.60 |
| 2017-09-30 |
$0.43B |
$0.07B |
6.32 |
| 2017-06-30 |
$0.24B |
$0.10B |
2.39 |
| 2017-03-31 |
$0.30B |
$0.11B |
2.70 |
| 2016-12-31 |
$0.34B |
$0.11B |
3.07 |
| 2016-09-30 |
$0.22B |
$0.09B |
2.59 |
| 2016-06-30 |
$0.22B |
$0.08B |
2.71 |
| 2016-03-31 |
$0.17B |
$0.06B |
2.62 |
| 2015-12-31 |
$0.22B |
$0.07B |
2.94 |
| 2015-09-30 |
$0.24B |
$0.04B |
6.69 |
| 2015-06-30 |
$0.37B |
$0.02B |
21.60 |
| 2015-03-31 |
$0.15B |
$0.02B |
7.20 |
| 2014-12-31 |
$0.16B |
$0.02B |
7.66 |
| 2014-09-30 |
$0.09B |
$0.01B |
6.31 |
| 2014-06-30 |
$0.08B |
$0.01B |
7.11 |
| 2014-03-31 |
$0.07B |
$0.01B |
7.84 |
| 2013-12-31 |
$0.09B |
$0.01B |
8.44 |
| 2013-09-30 |
$0.06B |
$0.01B |
7.48 |
| 2013-06-30 |
$0.08B |
$0.01B |
7.74 |
| 2013-03-31 |
$0.09B |
$0.01B |
10.98 |
| 2012-12-31 |
$0.11B |
$0.01B |
11.32 |
| 2012-09-30 |
$0.11B |
$0.01B |
11.33 |
| 2012-06-30 |
$0.11B |
$0.02B |
5.93 |
| 2012-03-31 |
$0.12B |
$0.02B |
6.49 |
| 2011-12-31 |
$0.07B |
$0.02B |
3.46 |
| 2011-09-30 |
$0.08B |
$0.02B |
4.10 |
| 2011-06-30 |
$0.09B |
$0.02B |
5.22 |
| 2011-03-31 |
$0.10B |
$0.02B |
6.01 |
| 2010-12-31 |
$0.11B |
$0.02B |
6.76 |
| 2010-09-30 |
$0.06B |
$0.01B |
7.42 |
| 2010-06-30 |
$0.07B |
$0.01B |
9.96 |
| 2010-03-31 |
$0.08B |
$0.01B |
9.50 |
| 2009-12-31 |
$0.08B |
$0.01B |
7.19 |
| 2009-09-30 |
$0.09B |
$0.02B |
5.48 |
| 2009-06-30 |
$0.10B |
$0.02B |
6.77 |
| 2009-03-31 |
$0.11B |
$0.01B |
8.84 |
| 2008-12-31 |
$0.12B |
$0.01B |
9.24 |
| 2008-09-30 |
$0.14B |
$0.02B |
9.26 |
| 2008-06-30 |
$0.15B |
$0.02B |
9.58 |
| 2008-03-31 |
$0.16B |
$0.02B |
10.51 |
| 2007-12-31 |
$0.16B |
$0.02B |
10.32 |
| 2007-09-30 |
$0.12B |
$0.01B |
12.61 |
| 2007-06-30 |
$0.13B |
$0.01B |
18.26 |
| 2007-03-31 |
$0.00B |
|
0.00 |
| 2006-09-30 |
$0.00B |
|
0.00 |
| 2006-06-30 |
$0.00B |
|
0.00 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$2.799B |
$0.261B |
|
AMICUS THERAPEUTICS is a biopharmaceutical company developing novel, oral therapeutics known as pharmacological chaperones for the treatment of a range of human genetic diseases. Pharmacological chaperone technology involves the use of small molecules that selectively bind to and stabilizeproteins in cells, leading to improved protein folding and trafficking, and increased activity. Amicus is initially targeting lysosomal storage disorders, which are severe, chronic genetic diseases with unmet medical needs. Amicus has completed Phase 2 clinical trials of Amigal(TM) for the treatment of Fabry disease and is conducting Phase 2 clinical trials of Plicera(TM) for the treatment of Gaucher disease.
|
